Michael Mollerus
Lawyers

Filters
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…
Royalty Pharma $6 billion senior notes offering
Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…
Emerson $1.6 billion acquisition of Open Systems International
Davis Polk is advising Emerson Electric Co. on its $1.6 billion acquisition of Open Systems International, Inc.
Emerson, headquartered in St. Louis, Missouri, is a global technology and…
Honeywell International $3 billion senior notes offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Honeywell International Inc. of $2.5 billion aggregate principal amount of its 0.483…
Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…
Clarivate $6.8 billion combination with CPA Global
Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock transaction, CPA Global shareholders will receive approximately 218…
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…
BRP Group $175.2 million follow-on offering
Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock, which includes 1,725,000 shares from the full exercise of the…
Uniti Group $250 million at-the-market stock offering
Davis Polk advised Uniti Group Inc., as issuer, in connection with a new SEC-registered at-the-market offering program by Uniti under which Uniti may issue and sell shares of its common…
Royalty Pharma $2.5 billion IPO
Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…